share_log

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K:外國發行人報告
美股SEC公告 ·  2024/08/26 20:01

Moomoo AI 已提取核心訊息

NeuroSense Therapeutics has received approval from the Nasdaq Hearings Panel for a listing extension on the Nasdaq Capital Market until October 31, 2024. This decision follows the company's hearing on August 1, where it presented its compliance plan to address the June 21 notice regarding insufficient stockholders' equity.The extension provides additional time for NeuroSense to demonstrate compliance with Nasdaq's Listing Rule 5550(b), which requires a minimum stockholders' equity of $2.5 million. The company must meet all required conditions within this timeframe to maintain its listing status.
NeuroSense Therapeutics has received approval from the Nasdaq Hearings Panel for a listing extension on the Nasdaq Capital Market until October 31, 2024. This decision follows the company's hearing on August 1, where it presented its compliance plan to address the June 21 notice regarding insufficient stockholders' equity.The extension provides additional time for NeuroSense to demonstrate compliance with Nasdaq's Listing Rule 5550(b), which requires a minimum stockholders' equity of $2.5 million. The company must meet all required conditions within this timeframe to maintain its listing status.
NeuroSense Therapeutics 已獲納斯達克聽證會小組批准,延長在納斯達克資本市場的上市期限至2024年10月31日。此決定是在公司於8月1日的聽證會後做出的,公司在聽證會上提出了其合規計劃,以解決6月21日關於股東權益不足的通知。此延長給予NeuroSense額外的時間來證明其符合納斯達克上市規則5550(b),該規則要求最低股東權益爲250萬美元。在此期限內,公司必須滿足所有要求的條件,以維持其上市狀態。
NeuroSense Therapeutics 已獲納斯達克聽證會小組批准,延長在納斯達克資本市場的上市期限至2024年10月31日。此決定是在公司於8月1日的聽證會後做出的,公司在聽證會上提出了其合規計劃,以解決6月21日關於股東權益不足的通知。此延長給予NeuroSense額外的時間來證明其符合納斯達克上市規則5550(b),該規則要求最低股東權益爲250萬美元。在此期限內,公司必須滿足所有要求的條件,以維持其上市狀態。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息